Company Active LTD

Company profile

Causeway Therapeutics Limited

CAUSEWAY - Home

Causeway Therapeutics Limited is a UK company with status active founded in 2015.

CRN
SC518335
Founded
2015
Age
10

Overview

Legal name
CAUSEWAY THERAPEUTICS LIMITED
Region
Unknown
Registered address
IMAGING CENTRE OF EXCELLENCE
QUEEN ELIZABETH UNIVERSITY HOSPITAL
GLASGOW
SCOTLAND
G51 4TF
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Jul
2027

Accounts due

Accounts Due

Next accounts due date

02 Nov
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Oct
2025

Accounts filed

Accounts

Last accounts made up date

19 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

20 Oct
2015

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2018
Funded years
2018, 2019, 2020, 2021
Age at first award
2 years

Projects

2021 Study

OsteoMiR -- a novel disease-modifying drug for the treatment of osteoarthritis.

1 Jan 2021 to 31 Dec 2023

Awarded
£0
Total cost £0

Osteoarthritis (OA) is the leading cause of disability in older adults with 1 in 8 being affected. Around 75% of people with OA report constant pain, with approximately 30% giving up work or reducing the number of hours they work due to the condition. The cost of OA in the USA and Europe has been estimated at 1-2.5% of GDP. Currently, there are no Disease...

2020 Feasibility Studies Lead participant

A first-in-patient trial of TenoMiR a microRNA replacement therapy for tendinopathy

1 Jun 2020 to 30 Nov 2020

Awarded
£230,896
Total cost £230,896

no public description

2019 Collaborative R&D Lead participant

A first-in-patient trial of TenoMiR a microRNA replacement therapy for tendinopathy.

1 Jul 2019 to 30 Sep 2021

Awarded
£1,228,273
Total cost £1,754,676

"One in 10 people will suffer from some form of tendinopathy during their lifetime, yet currently, the best treatment remains physiotherapy which only benefits 50% of cases. Despite recent advances in biological therapy, there remains no effective treatment for tendinopathy. Research at Causeway Therapeutics uncovered the molecular mechanism that causes d...

2018 Collaborative R&D Lead participant

microRNA therapy in tendon disease

1 May 2018 to 30 Apr 2020

Awarded
£1,308,892
Total cost £1,869,846

"One in 10 people will suffer from some form of tendinopathy during their lifetime, yet currently, the best treatment remains physiotherapy which only benefits 50% of cases. Despite recent advances in biological therapy, there remains no effective treatment for tendinopathy. Research at Causeway Therapeutics uncovered the molecular mechanism that causes d...

Product types

Collaborative R&D Feasibility Studies Study